Total Payments
$2,760
2024 Payments
$186.97
Companies
16
Transactions
171
Medicare Patients
1,694
Medicare Billing
$121,294
Payment Breakdown by Category
Food & Beverage$2,760 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,760 | 171 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,049 | 68 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $948.33 | 68 | $0 (2023) |
| Gilead Sciences, Inc. | $218.11 | 9 | $0 (2024) |
| Novo Nordisk Inc | $149.27 | 3 | $0 (2022) |
| Ironwood Pharmaceuticals, Inc | $87.15 | 5 | $0 (2023) |
| Daiichi Sankyo Inc. | $72.88 | 4 | $0 (2022) |
| Janssen Biotech, Inc. | $52.41 | 3 | $0 (2023) |
| PFIZER INC. | $37.79 | 2 | $0 (2023) |
| INTERCEPT PHARMACEUTICALS, INC. | $29.94 | 2 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.06 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $186.97 | 3 | ABBVIE INC. ($97.40) |
| 2023 | $417.93 | 23 | ABBVIE INC. ($179.27) |
| 2022 | $721.30 | 52 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($268.02) |
| 2021 | $1,434 | 93 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($646.28) |
All Payment Transactions
171 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/17/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $69.87 | General |
| Category: HCV | ||||||
| 08/27/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: ANTIBIOTIC | ||||||
| 06/04/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $97.40 | General |
| Category: VIROLOGY | ||||||
| 10/17/2023 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $33.72 | General |
| Category: VIROLOGY | ||||||
| 08/16/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: Immunology | ||||||
| 06/28/2023 | Ironwood Pharmaceuticals, Inc | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $19.58 | General |
| Category: GI | ||||||
| 06/28/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: Gastroenterology | ||||||
| 06/27/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: IMMUNOLOGY | ||||||
| 06/21/2023 | ABBVIE INC. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $12.91 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/14/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN, PLENVU | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: Gastroenterology | ||||||
| 06/08/2023 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $13.94 | General |
| Category: IMMUNOLOGY | ||||||
| 06/06/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $14.70 | General |
| Category: Immunology | ||||||
| 06/01/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: IMMUNOLOGY | ||||||
| 05/26/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.71 | General |
| 05/25/2023 | ABBVIE INC. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $10.20 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/24/2023 | Ironwood Pharmaceuticals, Inc | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $24.47 | General |
| Category: GI | ||||||
| 05/17/2023 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: VIROLOGY | ||||||
| 05/12/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/11/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.36 | General |
| 05/04/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: IMMUNOLOGY | ||||||
| 05/03/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $16.47 | General |
| Category: Immunology | ||||||
| 04/30/2023 | ABBVIE INC. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $18.64 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/29/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/27/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.31 | General |
| Category: Neuroscience | ||||||
| 04/25/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 11 | 366 | 645 | $77,995 | $31,156 |
| 2021 | 17 | 686 | 1,039 | $110,925 | $48,921 |
| 2020 | 7 | 642 | 788 | $113,115 | $41,218 |
Total Patients
1,694
Total Services
2,472
Medicare Billing
$121,294
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 108 | 283 | $48,110 | $20,809 | 43.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 46 | 69 | $7,935 | $2,873 | 36.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 29 | $7,685 | $2,661 | 34.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 19 | $4,370 | $1,978 | 45.3% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 23 | 29 | $1,450 | $1,257 | 86.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 26 | 27 | $4,050 | $763.98 | 18.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 23 | 59 | $2,950 | $441.92 | 15.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 57 | 80 | $800.00 | $233.80 | 29.2% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2022 | 12 | 12 | $540.00 | $109.94 | 20.4% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2022 | 12 | 21 | $105.00 | $28.07 | 26.7% |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | Office | 2022 | 16 | 17 | $0.17 | $0.16 | 94.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 146 | 302 | $51,435 | $24,322 | 47.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 100 | 152 | $17,480 | $8,508 | 48.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 38 | 38 | $10,070 | $3,954 | 39.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 18 | 26 | $5,980 | $2,817 | 47.1% |
| 87426 | Elisa detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 46 | 56 | $2,800 | $2,488 | 88.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 45 | 51 | $7,650 | $2,053 | 26.8% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 26 | 26 | $4,420 | $1,803 | 40.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 42 | 97 | $4,850 | $790.40 | 16.3% |
| 95981 | Electronic analysis of implanted gastric neurostimulator generator or transmitter | Office | 2021 | 16 | 29 | $1,305 | $652.50 | 50.0% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 24 | 30 | $1,950 | $494.74 | 25.4% |
| 0013A | Fee covid-19 vac 2 booster | Office | 2021 | 13 | 13 | $715.00 | $466.31 | 65.2% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis | Office | 2021 | 21 | 23 | $1,035 | $281.82 | 27.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 63 | 83 | $830.00 | $249.00 | 30.0% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2021 | 12 | 17 | $85.00 | $27.17 | 32.0% |
About Bridgett Green, NP-C
Bridgett Green, NP-C is a Nurse Practitioner healthcare provider based in Oxford, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/10/2015. The National Provider Identifier (NPI) number assigned to this provider is 1548633761.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Bridgett Green, NP-C has received a total of $2,760 in payments from pharmaceutical and medical device companies, with $186.97 received in 2024. These payments were reported across 171 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($2,760).
As a Medicare-enrolled provider, Green has provided services to 1,694 Medicare beneficiaries, totaling 2,472 services with total Medicare billing of $121,294. Data is available for 3 years (2020–2022), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Nurse Practitioner
- Location Oxford, MS
- Active Since 11/10/2015
- Last Updated 01/27/2023
- Taxonomy Code 363L00000X
- Entity Type Individual
- NPI Number 1548633761
Products in Payments
- XIFAXAN (Drug) $902.88
- HUMIRA (Biological) $230.57
- UBRELVY (Drug) $229.85
- MAVYRET (Drug) $186.33
- Rybelsus (Drug) $119.01
- QULIPTA (Drug) $97.04
- LINZESS (Drug) $89.41
- Linzess (Drug) $87.15
- INJECTAFER (Drug) $72.88
- Epclusa (Drug) $69.87
- STELARA (Biological) $52.41
- VIBERZI (Drug) $51.32
- CREON (Drug) $48.85
- RINVOQ (Biological) $46.51
- TRULANCE (Drug) $45.45
- VRAYLAR (Drug) $41.72
- XELJANZ (Drug) $37.79
- OCALIVA (Drug) $29.94
- SKYRIZI (Biological) $27.61
- GATTEX (Drug) $20.06
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nurse Practitioner Doctors in Oxford
Anita Box Thomas, Cfnp, CFNP
Nurse Practitioner — Payments: $3,938
Nurse Practitioner $3,938
Whitney Crow, Fnp-C, FNP-C
Nurse Practitioner — Payments: $2,796
Nurse Practitioner $2,796
Taylor Myers, Fnp-C, FNP-C
Nurse Practitioner — Payments: $2,547
Nurse Practitioner $2,547
Dr. Barbara Scarpa, Aprn, APRN
Nurse Practitioner — Payments: $1,782
Nurse Practitioner $1,782
Heather Hobbs, Aprn, APRN
Nurse Practitioner — Payments: $1,268
Nurse Practitioner $1,268
Sarah Bullock
Nurse Practitioner — Payments: $1,079
Nurse Practitioner $1,079